Latest news with #TDOC
Globe and Mail
5 days ago
- Business
- Globe and Mail
Teladoc Health to Announce Second Quarter 2025 Financial Results
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release second quarter 2025 results on Tuesday, July 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 606269. For international participants, please visit the following link for global dial-in numbers: A live audio webcast will also be available online at A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days. About Teladoc Health Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person's health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit
Yahoo
12-07-2025
- Business
- Yahoo
Teladoc (TDOC) Dips More Than Broader Market: What You Should Know
Teladoc (TDOC) closed at $8.32 in the latest trading session, marking a -5.56% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.22%. Coming into today, shares of the telehealth services provider had gained 22.87% in the past month. In that same time, the Medical sector lost 0.32%, while the S&P 500 gained 4.07%. Investors will be eagerly watching for the performance of Teladoc in its upcoming earnings disclosure. The company's upcoming EPS is projected at -$0.27, signifying a 3.57% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $621.69 million, indicating a 3.23% downward movement from the same quarter last year. For the full year, the Zacks Consensus Estimates project earnings of -$1.2 per share and a revenue of $2.52 billion, demonstrating changes of +79.56% and -2.12%, respectively, from the preceding year. Investors should also take note of any recent adjustments to analyst estimates for Teladoc. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 6.59% decrease. At present, Teladoc boasts a Zacks Rank of #3 (Hold). The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 64, which puts it in the top 26% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
04-07-2025
- Business
- Yahoo
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is actively leveraging artificial intelligence (AI) to revolutionize the delivery of healthcare, aiming to make it more personalized, scalable, and accessible. The company has strategically invested in expanding its AI capabilities, marked by the appointment of Mo Elshenawy — former president and chief technology officer (CTO) at Cruise and an AI expert — as its CTO in May. Elshenawy's expertise is expected to drive the development of an AI-powered healthcare platform that integrates diagnosis, treatment and delivery into a seamless and individualized experience. He emphasized that Hims & Hers is uniquely positioned to lead a healthcare transformation by using AI and data to deliver care that is smarter, more adaptive and deeply attuned to each patient's needs. To support this transformation, Hims & Hers recently raised $870 million in convertible notes in May, a portion of which is earmarked to advance AI tools, expand the company's data pipeline and enhance personalized treatments. This funding reflects HIMS' intention to modernize healthcare infrastructure using AI, not only to improve diagnostic accuracy but also to create a more intuitive and efficient patient journey. Their existing initiatives, such as the intelligent MedMatch routing system and efforts to deepen technological personalization, illustrate a clear roadmap for integrating AI into core operational processes. These developments position Hims & Hers at the forefront of AI-enabled healthcare delivery. Teladoc Health, Inc. TDOC is harnessing AI to strengthen its virtual care ecosystem, enhance diagnostics and personalize care delivery. Teladoc Health integrates AI across clinical workflows, using it for intelligent triage, patient engagement and predictive analytics to improve outcomes and operational efficiency. TDOC continues to scale its AI capabilities to support complex chronic condition management and behavioral health services. Through these innovations, Teladoc Health positions itself as a leading digital health provider, leveraging AI to expand access and elevate patient experiences. Tempus AI, Inc. TEM is deeply embedding AI across its precision medicine operations, using its proprietary AI platform, Lens, to analyze multimodal healthcare data. Tempus AI drives innovation in oncology and neurogenomics, notably through a collaboration with Northwestern University's Abrams Research Center to apply AI in Alzheimer's research. TEM also integrates AI into its diagnostics and data services, enabling real-time clinical decision support. Through this approach, Tempus AI is transforming healthcare by advancing targeted therapies, optimizing clinical workflows and scaling personalized treatment models. Shares of Hims & Hers have gained 95.7% year to date compared with the industry's growth of 19.7%. Image Source: Zacks Investment Research HIMS' forward 12-month P/S of 4.1X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of C. Image Source: Zacks Investment Research The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 174.1% improvement from 2024. Image Source: Zacks Investment Research Hims & Hers stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-06-2025
- Business
- Yahoo
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Teladoc (TDOC) shares rallied 14.4% in the last trading session to close at $7.89. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.3% gain over the past four weeks. Teladoc witnessed a price rise after Citron Research highlighted strong growth prospects following the company's Goldman Sachs presentation, where management revealed that embedding BetterHelp in employer health plans could drastically improve conversion rates. The recent acquisition of UpLift enables insurance billing. Citron also emphasized TDOC's AI edge and scale as key drivers of future profitability. Besides, Teladoc's competitive strengths lie in its unmatched integration of virtual care services, global reach and data-driven innovation. It offers a comprehensive suite of clinical services—from wellness and acute care to chronic and mental health management—through a highly scalable, secure and API-driven platform. Its proprietary engagement science, predictive analytics and personalized communications drive exceptional member utilization. This telehealth services provider is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +7.1%. Revenues are expected to be $621.69 million, down 3.2% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Teladoc, the consensus EPS estimate for the quarter has been revised 3.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TDOC going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Teladoc is a member of the Zacks Medical Services industry. One other stock in the same industry, LifeMD, Inc. (LFMD), finished the last trading session 3.1% lower at $14.3. LFMD has returned 28% over the past month. For LifeMD, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.02. This represents a change of +89.5% from what the company reported a year ago. LifeMD currently has a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Graco Inc. (GGG) : Free Stock Analysis Report Stem, Inc. (STEM) : Free Stock Analysis Report Compugen Ltd. (CGEN) : Free Stock Analysis Report Modine Manufacturing Company (MOD) : Free Stock Analysis Report Liberty Media Corporation - Liberty Formula One Series A (FWONA) : Free Stock Analysis Report Sutro Biopharma, Inc. (STRO) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report LifeMD, Inc. (LFMD) : Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report Indivior PLC (INDV) : Free Stock Analysis Report Cartesian Therapeutics, Inc. (RNAC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
24-06-2025
- Business
- Yahoo
Teladoc (TDOC) Stock Trades Up, Here Is Why
Shares of digital medical services platform Teladoc Health (NYSE:TDOC) jumped 10.9% in the afternoon session after Citron Research published a report highlighting the company's growth potential following Teladoc's impressive updates at a Goldman Sachs Healthcare conference. TDOC's management noted that roughly 80% of the 4 million people who sign up for BetterHelp drop off or fail to convert because the system is cash only and also expensive. So, embedding BetterHelp into employer health benefits could help significantly improve conversion. Citron Research pointed to Teladoc's recent acquisition of UpLift Health Technologies as a "transformational" development, suggesting it will significantly boost revenue by enabling insurance billing for BetterHelp services, which were previously cash-pay only. The argument is that a 1% lift in conversion (@ an annual fee of 1,250) could add $40 million to TDOC's annual sales. Lastly, Citron highlighted the potential for AI to drive profits, noting that Teladoc's scale will be tough to replicate. The shares closed the day at $7.90, up 14.5% from previous close. Is now the time to buy Teladoc? Access our full analysis report here, it's free. Teladoc's shares are extremely volatile and have had 40 moves greater than 5% over the last year. But moves this big are rare even for Teladoc and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 17 days ago when the stock gained 5.7% on the news that the major indices rebounded, as the Bureau of Labor Statistics report revealed a resilient labor market with non-farm payrolls rising by 139,000 in May 2025, significantly above the consensus forecast of 125,000. Notably, a stable labor market often supports consumer spending, which is a key driver of economic growth, which means the report could help ease some of the recession fears that gripped markets. Also, it is possible some investors were buying the dip following the sell-off at the end of the previous week. Teladoc is down 15.7% since the beginning of the year, and at $8.03 per share, it is trading 44% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc's shares 5 years ago would now be looking at an investment worth $40.54. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
